Ligand binding by estrogen receptor beta attached to nanospheres measured by fluorescence correlation spectroscopy

被引:9
作者
Allen, NW [1 ]
Thompson, NL
机构
[1] Univ N Carolina, Dept Chem, Asheville, NC 28804 USA
[2] Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA
关键词
nuclear receptor; FCS; kinetics; SERM; estradiol; steroid receptor coactivator;
D O I
10.1002/cyto.a.20279
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Although many indirect methods have been chosen to study the system of estrogen receptor ligand binding, an ideal method is fluorescence correlation spectroscopy (FCS). FCS is nondestructive to the sample, uses very small sample volumes, and operates well within physiological concentration ranges. The methodology was developed to biotinylate the estrogen receptor P-ligand binding domain (ER beta-LBD) using biotin with a very short spacer and to then attach this protein to a 40 nm neutravidin-coated bead (nanosphere). Diffusional FCS data were obtained for a fluorescently labeled coactivator peptide, steroid receptor coactivator peptide-1 (A-SRC-1(2)), in the absence and presence of bead-bound ER beta-LBD. Data were also acquired in the presence of one of the endogenous ligands for ER beta, 17 beta-estradiol, and with tamoxifen. The bead strategy resulted in a decreased receptor diffusion coefficient and consequent increase in the decay time of the FCS auto-correlation functions for receptor-bound, labeled SRG 1(2). Thus, free and bound coactivators were much more readily distinguished by FCS. Discrimination between the fluorescently labeled unbound and bound species could be determined in autocorrelation functions obtained in as few as 30 s. The advantage of using FCS with the ER beta-LBD: bead methodology is the ability to obtain reliable and reproducible data in a short time frame. (c) 2006 International Society for Analytical Cytology.
引用
收藏
页码:524 / 532
页数:9
相关论文
共 28 条
[1]   Molecular targets for breast cancer therapy and prevention [J].
Bange, J ;
Zwick, E ;
Ullrich, A .
NATURE MEDICINE, 2001, 7 (05) :548-552
[2]   Hormone replacement therapy in relation to breast cancer [J].
Chen, CL ;
Weiss, NS ;
Newcomb, P ;
Barlow, WN ;
White, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (06) :734-741
[3]   Novel fluorescence based receptor binding assay method for receptors lacking ligand conjugates with preserved affinity:: Study on estrogen receptor α [J].
Christoph, S ;
Meyer-Almes, FJ .
BIOPOLYMERS, 2003, 72 (04) :256-263
[4]   Serum estradiol level and risk of breast cancer during treatment with raloxifene [J].
Cummings, SR ;
Duong, T ;
Kenyon, E ;
Cauley, JA ;
Whitehead, M ;
Krueger, KA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (02) :216-220
[5]   MENOPAUSAL ESTROGEN REPLACEMENT THERAPY AND BREAST-CANCER [J].
DUPONT, WD ;
PAGE, DL .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) :67-72
[6]   Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor [J].
Gee, AC ;
Carlson, KE ;
Martini, PGV ;
Katzenellenbogen, BS ;
Katzenellenbogen, JA .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (11) :1912-1923
[7]  
Iannone MA, 2001, CYTOMETRY, V44, P326, DOI 10.1002/1097-0320(20010801)44:4<326::AID-CYTO1124>3.0.CO
[8]  
2-4
[9]   Fluorescence correlation spectroscopy: the technique and its applications [J].
Krichevsky, O ;
Bonnet, G .
REPORTS ON PROGRESS IN PHYSICS, 2002, 65 (02) :251-297
[10]   Cloning of a novel estrogen receptor expressed in rat prostate and ovary [J].
Kuiper, GGJM ;
Enmark, E ;
PeltoHuikko, M ;
Nilsson, S ;
Gustafsson, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (12) :5925-5930